Test Could Predict Which Children With T-Cell ALL Are Best Candidates for Clinical Trials
ScienceDaily (July 25, 2010) — A genetic clue uncovered by Dana-Farber Cancer Institute scientists enables doctors to predict, for the first time, which children with T-cell acute lymphoblastic leukemia (T-ALL) are unlikely to benefit from standard chemotherapy for the disease and should therefore be among the first to receive new treatments in future clinical trials.
FDA Sets Priority Review Schedule for BMS and Otsuka’s sNDA for Sprycel as First-Line CML Therapy
FDA accepted an sNDA for Bristol-Myers Squibb (BMS) and Otsuka Pharmaceutical’s chronic myeloid leukemia (CML) drug, Sprycel®, and has granted the application priority review status. The sNDA specifically relates to use of the BCR-ABL inhibitor for the treatment of adult patients with newly diagnosed CML in chronic phase. The projected FDA action data is October...
EUSA Pharma Grants Japanese Rights to Erwinase(R) Oncology Therapy to Ohara Pharmaceutical
OXFORD, England and LANGHORNE, Pennsylvania, July 6, 2010 /PRNewswire/ -- EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has granted the Japanese development and commercialization rights to its oncology therapy Erwinase(R) to Ohara Pharmaceutical Company Limited. The agreement represents the first product...
Findings could lead to less invasive treatments for acute lymphoblastic leukemia
Montreal, June 16, 2010 – A team of researchers from the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal have defined for the first time the mechanism behind three cancer-causing genes in acute lymphoblastic leukemia. Published in the journal Genes and Development, the findings offer insight on the complex interaction between...
THURSDAY, May 13 (HealthDay News) -- Researchers have linked a genetic pattern to the likelihood that patients with a severe form of childhood leukemia will relapse.
The finding could lead doctors to screen for the pattern and treat those who have it more aggressively from the time of diagnosis, the researchers added.
The kids in question have T-cell acute lymphoblastic leukemia, which accounts for about 15 percent of childhood leukemia...
